NCT06814730 - A Study to Assess THN391 in Subjects With Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

September 30, 2026

Conditions

Alzheimer Disease, Early Onset

Interventions

DRUG

THN391

THN391, IV infusion, 3\*Q4W (every 4 weeks)

DRUG

Placebo

Placebo for comparison with THN391, IV infusion, 3\*Q4W

Trial Locations (4)

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

CTC-Netherlands, Groningen

RECRUITING

Scottish Brain Sciences, Edinburgh

RECRUITING

University College London Hospitals, London

All Listed Sponsors

lead

Therini Bio, Inc.

INDUSTRY